Lung cancer drug brigatinib under Real-World watch in south korea
NCT ID NCT04592523
First seen Jan 04, 2026
Summary
This study is monitoring the safety and effectiveness of the drug brigatinib in adults with a specific type of advanced lung cancer (ALK-positive NSCLC) in South Korea. Researchers will track side effects and how well the drug controls the cancer in 257 patients who are starting brigatinib for the first time. The goal is to see how the drug performs in everyday medical practice, outside of a controlled clinical trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Pusan National University Hospital
RECRUITINGBusan, 49241, South Korea
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.